Equasens Société anonyme (0R9T.L)
EUR 44.15
(1.03%)
EUR 44.15
(1.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 71.29 Million EUR | -0.55% |
| 2022 | 67.36 Million EUR | 7.24% |
| 2021 | 63.76 Million EUR | 15.57% |
| 2020 | 55.82 Million EUR | 9.84% |
| 2019 | 50.2 Million EUR | 14.64% |
| 2018 | 44.22 Million EUR | 14.87% |
| 2017 | 39.55 Million EUR | 10.45% |
| 2016 | 34.85 Million EUR | 11.82% |
| 2015 | 31.17 Million EUR | 11.31% |
| 2014 | 28 Million EUR | 7.94% |
| 2013 | 27.13 Million EUR | 14.87% |
| 2012 | 22.58 Million EUR | 14.4% |
| 2011 | 20.66 Million EUR | 3.45% |
| 2010 | 18.8 Million EUR | 13.02% |
| 2009 | 16.8 Million EUR | 846.79% |
| 2008 | -2.26 Million EUR | 78.3% |
| 2007 | -10.41 Million EUR | -184.82% |
| 2006 | 12.28 Million EUR | 8.99% |
| 2005 | 11.26 Million EUR | 20.86% |
| 2004 | 9.32 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 13.73 Million EUR | -7.96% |
| 2024 Q2 | 13.73 Million EUR | 0.0% |
| 2023 FY | - EUR | -0.55% |
| 2023 Q2 | 33.55 Million EUR | 133.74% |
| 2023 Q3 | 14.92 Million EUR | -55.51% |
| 2023 Q4 | 14.92 Million EUR | 0.0% |
| 2023 Q1 | 14.35 Million EUR | -61.11% |
| 2022 Q4 | 36.9 Million EUR | 0.0% |
| 2022 Q1 | 15.8 Million EUR | -50.33% |
| 2022 FY | - EUR | 7.24% |
| 2022 Q2 | 31.61 Million EUR | 100.0% |
| 2021 Q2 | 29.76 Million EUR | 100.0% |
| 2021 FY | - EUR | 15.57% |
| 2021 Q3 | 15.92 Million EUR | -46.51% |
| 2021 Q1 | 14.88 Million EUR | -51.87% |
| 2021 Q4 | 31.82 Million EUR | 99.91% |
| 2020 Q1 | 12.5 Million EUR | -50.91% |
| 2020 Q2 | 24.74 Million EUR | 97.87% |
| 2020 FY | - EUR | 9.84% |
| 2020 Q3 | 15.4 Million EUR | -37.74% |
| 2020 Q4 | 30.92 Million EUR | 100.71% |
| 2019 Q2 | 22.82 Million EUR | 100.04% |
| 2019 Q4 | 25.47 Million EUR | 99.06% |
| 2019 Q1 | 11.4 Million EUR | -53.18% |
| 2019 FY | - EUR | 14.64% |
| 2019 Q3 | 12.79 Million EUR | -43.93% |
| 2018 Q2 | 19.85 Million EUR | 100.0% |
| 2018 FY | - EUR | 14.87% |
| 2018 Q4 | 24.36 Million EUR | 100.0% |
| 2018 Q3 | 12.18 Million EUR | -38.63% |
| 2018 Q1 | 9.92 Million EUR | -51.09% |
| 2017 Q1 | 9.1 Million EUR | -48.28% |
| 2017 Q3 | 10.14 Million EUR | -44.25% |
| 2017 Q4 | 20.29 Million EUR | 100.0% |
| 2017 Q2 | 18.2 Million EUR | 100.0% |
| 2017 FY | - EUR | 10.45% |
| 2016 Q4 | 17.59 Million EUR | 100.0% |
| 2016 FY | - EUR | 11.82% |
| 2016 Q2 | 17.25 Million EUR | 100.0% |
| 2016 Q3 | 8.79 Million EUR | -49.03% |
| 2016 Q1 | 8.62 Million EUR | -45.17% |
| 2015 Q1 | 7.71 Million EUR | -43.07% |
| 2015 Q3 | 7.86 Million EUR | -49.01% |
| 2015 Q2 | 15.43 Million EUR | 100.0% |
| 2015 FY | - EUR | 11.31% |
| 2015 Q4 | 15.73 Million EUR | 100.0% |
| 2014 Q4 | 13.55 Million EUR | 100.0% |
| 2014 Q1 | 7.22 Million EUR | -42.77% |
| 2014 FY | - EUR | 7.94% |
| 2014 Q2 | 14.45 Million EUR | 100.0% |
| 2014 Q3 | 6.77 Million EUR | -53.1% |
| 2013 Q3 | 6.31 Million EUR | -52.61% |
| 2013 Q1 | 6.65 Million EUR | 0.0% |
| 2013 FY | - EUR | 14.87% |
| 2013 Q2 | 13.31 Million EUR | 100.0% |
| 2013 Q4 | 12.62 Million EUR | 100.0% |
| 2012 FY | - EUR | 14.4% |
| 2011 FY | - EUR | 3.45% |
| 2010 FY | - EUR | 13.02% |
| 2009 FY | - EUR | 846.79% |
| 2008 FY | - EUR | 78.3% |
| 2007 FY | - EUR | -184.82% |
| 2006 FY | - EUR | 8.99% |
| 2005 FY | - EUR | 20.86% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cegedim SA | 95.25 Million EUR | 25.146% |
| Guerbet SA | 90.09 Million EUR | 20.862% |
| Nexus AG | 53.43 Million EUR | -33.441% |
| Bastide Le Confort Médical SA | 110.32 Million EUR | 35.373% |
| Revenio Group Oyj | 30.09 Million EUR | -136.952% |
| Drägerwerk AG & Co. KGaA | 318.33 Million EUR | 77.602% |
| Sartorius Aktiengesellschaft | 811.2 Million EUR | 91.211% |
| LNA Santé SA | 144.63 Million EUR | 50.704% |
| Siemens Healthineers AG | 4.22 Billion EUR | 98.312% |
| Medios AG | 52.81 Million EUR | -34.995% |
| Stratec SE | 39.82 Million EUR | -79.049% |